Healthcare >> CEO Interviews >> September 23, 2003
ABRAHAM ABUCHOWSKI is a Founder of Prolong Pharmaceuticals, Inc., and
will serve as the company's Chairman of the Board and Chief Executive
Officer. Dr. Abuchowski was the Founder and past Chairman and CEO of
Enzon, Inc., a multibillion-dollar, biopharmaceutical company that
specializes in PEGylation technology. During his 13 years at Enzon
(1983-1996), Dr. Abuchowski successfully commercialized PEGylation by
gaining FDA approval for three protein-based drugs. Dr. Abuchowski was
instrumental in helping Enzon mature from a developmental stage company
to a fully integrated publicly traded biopharmaceutical company. Dr.
Abuchowski holds a BS and PhD in Biochemistry from Rutgers University.
He is an internationally recognized authority on drug delivery and has
published numerous scientific papers and several book chapters on
therapeutic products. In 1994, Dr. Abuchowski founded and served as the
first Chairman of the Biotechnology Council of New Jersey. Dr.
Abuchowski is one of New Jersey's top entrepreneurs and is recognized at
both the state and national level as an outstanding bioscience
executive. Profile
Pharmaceuticals?
Dr. Abuchowski: The company is called Prolong Pharmaceuticals. We
started developing the company in 1997
